{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:04:45Z","timestamp":1794002685228,"version":"4.8.0"},"reference-count":53,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kyoto University Hospital","award":["0709992110"],"award-info":[{"award-number":["0709992110"]}]},{"name":"Time Therapeutics, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,5,24]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) is one of the most common causes of dementia. Pathogenic variants in the presenilin 1 (PSEN1) gene are the most frequent cause of early-onset AD. Medications for patients with AD bearing PSEN1 mutation (PSEN1-AD) are limited to symptomatic therapies and no established radical treatments are available. Induced pluripotent stem cell (iPSC)-based drug repurposing identified bromocriptine as a therapeutic candidate for PSEN1-AD. In this study, we used an enrichment strategy with iPSCs to select the study population, and we will investigate the safety and efficacy of an orally administered dose of bromocriptine in patients with PSEN1-AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a multicentre, randomised, placebo-controlled trial. AD patients with PSEN1 mutations and a Mini Mental State Examination-Japanese score of \u226425\u2009will be randomly assigned, at a 2:1 ratio, to the trial drug or placebo group (\u22654 patients in TW-012R and \u22652 patients in placebo). This clinical trial consists of a screening period, double-blind phase (9 months) and extension phase (3 months). The double-blind phase for evaluating the efficacy and safety is composed of the low-dose maintenance period (10\u2009mg\/day), high-dose maintenance period (22.5\u2009mg\/day) and tapering period of the trial drug. Additionally, there is an open-labelled active drug extension period for evaluating long-term safety. Primary outcomes are safety and efficacy in cognitive and psychological function. Also, exploratory investigations for the efficacy of bromocriptine by neurological scores and biomarkers will be conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The proposed trial is conducted according to the Declaration of Helsinki, and was approved by the Institutional Review Board (K070). The study results are expected to be disseminated at international or national conferences and published in international journals following the peer-review process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      jRCT2041200008,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04413344\">NCT04413344<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-051343","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T12:40:09Z","timestamp":1625056809000},"page":"e051343","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Repurposing bromocriptine for A\u03b2 metabolism in Alzheimer\u2019s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer\u2019s disease with presenilin 1 (PSEN1) mutations"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct04413344","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Takayuki","family":"Kondo","sequence":"first","affiliation":[{"name":"Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Banno","sequence":"additional","affiliation":[{"name":"Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"},{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Okunomiya","sequence":"additional","affiliation":[{"name":"Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"},{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Amino","sequence":"additional","affiliation":[{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Endo","sequence":"additional","affiliation":[{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Nakakura","sequence":"additional","affiliation":[{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-9869","authenticated-orcid":false,"given":"Ryuji","family":"Uozumi","sequence":"additional","affiliation":[{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"},{"name":"Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akemi","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harue","family":"Tada","sequence":"additional","affiliation":[{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-7262","authenticated-orcid":false,"given":"Hidehiro","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-4943","authenticated-orcid":false,"given":"Akihiro","family":"Shindo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Taruno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takakuni","family":"Maki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Suehiro","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Osaka University Graduate School of Medicine, Suita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuishin","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutomi","family":"Kanemaru","sequence":"additional","affiliation":[{"name":"Department of Stroke, Tokyo Metropolitan Geriatric Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[{"name":"Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Shigenobu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Asakayama Hospital, Sakai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kutoku","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kawasaki Medical School, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Sunada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kawasaki Medical School, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Kawakatsu","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Fukushima Medical University Aizu Medical Center, Aizu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Shiota","sequence":"additional","affiliation":[{"name":"Time Therapeutics, Inc, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Time Therapeutics, Inc, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Uchikawa","sequence":"additional","affiliation":[{"name":"Towa Pharmaceutical Co., Ltd, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Tomimoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4736-9537","authenticated-orcid":false,"given":"Haruhisa","family":"Inoue","sequence":"additional","affiliation":[{"name":"Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan"},{"name":"Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"2025121220011544000_11.6.e051343.1","unstructured":"Alzheimer\u2019s Disease International . World Alzheimer report 2019: attitudes to dementia. London: Alzheimer\u2019s Disease International, 2019."},{"key":"2025121220011544000_11.6.e051343.2","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"65","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement"},{"key":"2025121220011544000_11.6.e051343.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30193-4"},{"key":"2025121220011544000_11.6.e051343.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0019-5"},{"key":"2025121220011544000_11.6.e051343.5","doi-asserted-by":"publisher","DOI":"10.1038\/383710a0"},{"key":"2025121220011544000_11.6.e051343.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(00)80230-5"},{"key":"2025121220011544000_11.6.e051343.7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"2025121220011544000_11.6.e051343.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2005.03578.x"},{"key":"2025121220011544000_11.6.e051343.9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006304"},{"key":"2025121220011544000_11.6.e051343.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.10.109"},{"key":"2025121220011544000_11.6.e051343.11","unstructured":"WIPO|PCT . WIPO PCT\/JP2016\/089217, 2020. Available: http:\/\/ips-cell.net\/e\/patent\/docs\/AJ139.pdf"},{"key":"2025121220011544000_11.6.e051343.12","unstructured":"United States Patent Application Publication, INOUE . US20190008860A1, 2020. Available: https:\/\/patents.google.com\/patent\/US20190008860A1\/en?q=KONDO+Inoue+Bromocriptine+alzheimer&oq=KONDO+Inoue+Bromocriptine+alzheimer"},{"key":"2025121220011544000_11.6.e051343.13","unstructured":"Towa Pharmaceutical Co., Ltd . Interview form bromocriptine tablets 2.5 mg \u201cTowa\u201d, 20. Available: https:\/\/med.towayakuhin.co.jp\/medical\/product\/product.php?id=T001706201703011557043R"},{"key":"2025121220011544000_11.6.e051343.14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\"s & Dementia"},{"key":"2025121220011544000_11.6.e051343.15","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders, fifth edition: DSM-5. Washington, DC: American Psychiatric Publishing, 2013: 611\u20134.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2025121220011544000_11.6.e051343.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.09.012"},{"key":"2025121220011544000_11.6.e051343.17","unstructured":"JFAD . Japanese Familial Alzheimer\u2019s Disease (JFAD) database, 2020. Available: http:\/\/www.alzdb.org\/jfad\/"},{"key":"2025121220011544000_11.6.e051343.18","unstructured":"FY 2013 subsidy for geriatric health promotion, project for geriatric health enhancement: report of research project on the support system for individuals with familial alzheimer\u2019s disease and their families 2013 https:\/\/www.med.osaka-cu.ac.jp\/other\/doc\/project-20140331a.pdf"},{"key":"2025121220011544000_11.6.e051343.19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jfma.2015.08.004","article-title":"A systematic review of familial Alzheimer\"s disease: differences in presentation of clinical features among three mutated genes and potential ethnic differences","volume":"115","author":"Shea","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"2025121220011544000_11.6.e051343.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30229-0"},{"key":"2025121220011544000_11.6.e051343.21","unstructured":"Sun Pharma Japan Ltd . Interview form Parlodel tablets 2.5 Mg, 2021. Available: https:\/\/medical.mt-pharma.co.jp\/di\/file\/dc\/plo.pdf"},{"key":"2025121220011544000_11.6.e051343.22","doi-asserted-by":"publisher","DOI":"10.1037\/\/1040-3590.2.3.298"},{"key":"2025121220011544000_11.6.e051343.23","unstructured":"Saxton J , McGonigle K , Swihart A . Severe impairment battery (SIB). London, UK: Pearson Assessment, 1993."},{"key":"2025121220011544000_11.6.e051343.24","first-page":"683","article-title":"Reliability, validity and clinical availability of a Japanese version of Severe Impairment Battery (SIB) and a Japanese version of modified Alzheimer\u2019s Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL)","volume":"16","author":"Niina","year":"2005","journal-title":"Jpn J Geriatr Psychiatry"},{"key":"2025121220011544000_11.6.e051343.25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.12.2308"},{"key":"2025121220011544000_11.6.e051343.26","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.48.5_suppl_6.10s"},{"key":"2025121220011544000_11.6.e051343.27","first-page":"266","article-title":"[Japanese version of the Neuropsychiatric Inventory--a scoring system for neuropsychiatric disturbance in dementia patients]","volume":"49","author":"Hirono","year":"1997","journal-title":"No To Shinkei"},{"key":"2025121220011544000_11.6.e051343.28","first-page":"1217","article-title":"Development of a new rating scale for dementia in the elderly: mental function impairment scale (MENFIS) (in Japanese)","volume":"2","author":"Homma","year":"1991","journal-title":"Jpn J Geriatr Psychiatry"},{"key":"2025121220011544000_11.6.e051343.29","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"2025121220011544000_11.6.e051343.30","first-page":"168","article-title":"Reexamination of the validity and reliability of the Japanese version of the Mini-Mental state examination (MMSE-J)","volume":"18","author":"Sugishita","year":"2016","journal-title":"Japanese Journal of Cognitive Neuroscience"},{"key":"2025121220011544000_11.6.e051343.31","first-page":"91","article-title":"The validity and reliability of the Japanese version of the Mini- Mental State Examination(MMSE-J) with the original procedure of the attention and calculation task(2001)","volume":"20","author":"Sugishita","year":"2018","journal-title":"Japanese Journal of Cognitive Neuroscience"},{"key":"2025121220011544000_11.6.e051343.32","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Galasko","year":"2002","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2025121220011544000_11.6.e051343.33","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"2025121220011544000_11.6.e051343.34","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(91)90040-V"},{"key":"2025121220011544000_11.6.e051343.35","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3143\/geriatrics.51.445","article-title":"[Reliability and validity of the Japanese version of the Apathy Evaluation Scale]","volume":"51","author":"Kasai","year":"2014","journal-title":"Nihon Ronen Igakkai Zasshi"},{"key":"2025121220011544000_11.6.e051343.36","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of fully automated plasma assays as screening tests for Alzheimer disease-related \u03b2-amyloid status","volume":"76","author":"Palmqvist","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025121220011544000_11.6.e051343.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104960"},{"key":"2025121220011544000_11.6.e051343.38","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo clinic study on aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol"},{"key":"2025121220011544000_11.6.e051343.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5"},{"key":"2025121220011544000_11.6.e051343.40","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0206-8"},{"key":"2025121220011544000_11.6.e051343.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202753"},{"key":"2025121220011544000_11.6.e051343.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70090-0"},{"key":"2025121220011544000_11.6.e051343.43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243910","article-title":"Association between objectively measured walking steps and sleep in community-dwelling older adults: a prospective cohort study","volume":"15","author":"Kimura","year":"2020","journal-title":"PLoS One"},{"key":"2025121220011544000_11.6.e051343.44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neures.2004.03.004","article-title":"Quantitative magnetic detection of finger movements in patients with Parkinson\"s disease","volume":"49","author":"Kandori","year":"2004","journal-title":"Neurosci Res"},{"key":"2025121220011544000_11.6.e051343.45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.11336\/jjcrs.7.19","article-title":"Assessment of finger motor skills in individuals with mild cognitive impairment and patients with Alzheimer\u2019s disease: Relationship between finger-to-thumb tapping and cognitive function","volume":"7","author":"Suzumura","year":"2016","journal-title":"Japanese J Compr Rehabil Sci"},{"key":"2025121220011544000_11.6.e051343.46","first-page":"128","article-title":"Biodistribution and radiation dosimetry of the amyloid imaging agent 11C-PiB in humans","volume":"48","author":"Scheinin","year":"2007","journal-title":"J Nucl Med"},{"key":"2025121220011544000_11.6.e051343.47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11307-019-01367-w","article-title":"Preclinical safety evaluation and human dosimetry of [18F]MK-6240, a Novel PET tracer for imaging neurofibrillary tangles","volume":"22","author":"Koole","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"2025121220011544000_11.6.e051343.48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039216"},{"key":"2025121220011544000_11.6.e051343.49","doi-asserted-by":"publisher","DOI":"10.1038\/nature25456"},{"key":"2025121220011544000_11.6.e051343.50","first-page":"398","article-title":"Analyses of natural courses of Japanese patients with Alzheimer\"s disease using placebo data from placebo-controlled, randomized clinical trials: Japanese study on the estimation of clinical course of Alzheimer\"s disease","volume":"5","author":"Watanabe","year":"2019","journal-title":"Alzheimers Dement"},{"key":"2025121220011544000_11.6.e051343.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73729-2"},{"key":"2025121220011544000_11.6.e051343.52","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00635-0"},{"key":"2025121220011544000_11.6.e051343.53","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jagp.2020.05.016","article-title":"Clinical trials and tribulations in the COVID-19 era","volume":"28","author":"Weinberg","year":"2020","journal-title":"Am J Geriatr Psychiatry"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-051343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:01:26Z","timestamp":1765598486000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-051343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,30]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bmjopen-2021-051343"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-051343","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}